Boston Scientific Corp. Stock Plummets to New 52-Week Low at USD 60.91

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 60.91 on April 7, 2026. This decline reflects a challenging year for the company, with its stock performance down 20.1% over the past year, contrasting sharply with the S&P 500's gain of 30.71% during the same period. As a large-cap player in the retailing industry, Boston Scientific boasts a market capitalization of approximately USD 121.9 billion. The company's price-to-earnings (P/E) ratio stands at 36.00, indicating a premium valuation compared to some peers. Additionally, Boston Scientific maintains a debt-to-equity ratio of 0.39, suggesting a relatively conservative approach to leveraging. Despite the current stock price challenges, the company has a return on equity of 13.88%, reflecting its ability to generate profits from shareholders' equity. The price-to-book ratio is noted at 5.03, which may indicate how the market values the company's assets relative to its stock price. Overall, these metrics provide a comprehensive view of Boston Scientific's current market position amidst its recent stock performance.